89151-46-2

Basic information

• Product Name: 1-Boc-4-(2-iodoethyl)piperidine
• Synonyms: 1-Boc-4-(2-iodoethyl)piperidine;1-Piperidinecarboxylic acid, 4-(2-iodoethyl)-, 1,1-dimethylethyl ester;1-Boc-4-(2-Iodoethyl)Piperidine(WX630127);TERT-BUTYL 4-(2-IODOETHYL)PIPERIDINE-1-CARBOXYLATE
• CAS NO: 89151-46-2
• Molecular Formula: C₁₂H₂₂INO₂
• Molecular Weight: 339.21305
• Mol File: 89151-46-2.mol
• Article Data: 40

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Boc-4-(2-iodoethyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-(2-iodoethyl)piperidine(89151-46-2)
• EPA Substance Registry System: 1-Boc-4-(2-iodoethyl)piperidine(89151-46-2)

Safety Data

• Hazardous Substances Data: 89151-46-2(Hazardous Substances Data)

Usage

Molecular weight

386.29 g/mol

Type of compound

Chemical compound

Derivative of

Piperidine (a heterocyclic ring compound)

Common use

Synthesis of pharmaceuticals and agrochemicals

Presence of 1-Boc (tert-butoxycarbonyl) protecting group

Indicates its use as an intermediate in organic synthesis

Role in organic synthesis

Production of other drugs and organic compounds

Addition of 2-iodoethyl group

Provides reactivity towards nucleophilic substitution reactions

Upstream product

• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 288-32-4 1H-imidazole 
• 98-59-9 p-toluenesulfonyl chloride 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 89151-45-1 tert-butyl-4-(2-(tosyloxy)ethyl)piperidine-1-carboxylate 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 163213-39-6 5-[2-(1-tert-Butoxycarbonyl-piperidin-4-yl)-ethyl]-4-oxo-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carboxylic acid methyl ester 
• 301225-86-5 4-(2-((4-fluorophenyl)thio)-1-ethyl)-1-tert-butoxycarbonyl-piperidine 
• 519060-62-9 4-[3-(4-fluoro-phenyl)-3-methoxycarbonyl-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1026237-30-8 4-{2-[5-(2-benzenesulfonylamino-2-carboxy-ethylcarbamoyl)-thieno[3,2-b]thiophen-2-yl]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 1026318-75-1 4-{2-[5-(2-benzenesulfonylamino-2-carboxy-ethylcarbamoyl)-thieno[2,3-b]thiophen-2-yl]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 705951-01-5 4-[2-((2S,3R)-2-Benzyloxycarbonyl-4-oxo-azetidin-3-yl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 301225-88-7 4-(2-((4-fluorophenyl)sulfonyl)-1-ethyl)piperidine 
• 519060-67-4 phenyl-(2-piperidin-4-yl-ethyl)-phosphinic acid methyl ester 
• 519060-64-1 2-(4-fluoro-phenyl)-4-piperidin-4-yl-butyric acid methyl ester 
• 519060-63-0 4-[3-(4-fluoro-phenyl)-4-hydroxy-butyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 146093-46-1 4-(2-aminoethyl)-1-piperidinecarboxylic acid tert-butyl ester 
• 163213-40-9 5-[2-(1-tert-Butoxycarbonyl-piperidin-4-yl)-ethyl]-4-oxo-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carboxylic acid 
• 163212-43-9 L 738167 

Relevant articles and documents

Synthesis and J-Dimer Formation of Tetrapyrazinoporphyrazines with Different Functional Groups for Potential Biomolecular Probe Applications

Though tetrapyrazinoporphyrazines (TPyzPzs) are generally presented as universal dark quenchers for oligonucleotide probes, the availability of TPyzPzs bearing different functional groups suitable for attachment to 3′, and 5′ ends or intrastrand positions remains rather limited. Therefore, a synthetic route to hexa(bis(2-methoxyethyl)amino) or hexa(diethylamino) TPyzPzs functionalized by an azide, hydroxy, or carboxy group or their combinations was developed. Studies of self-assembly into J-dimers in nonpolar solvents and their stability upon titration with pyridine (association constants, KP values, ranging 0.32–12.7×102 M?1) revealed that smaller peripheral substituents and functionalization of TPyzPzs improves the stability of J-dimers. ΦΔ and ΦF were low for the monomers (ΦFΔF=0.027, ΦΔ=0.28).

ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE

Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response.

ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER

Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.